Chief Technology Officer (2025); Chief Scientific Officer (effective January 1, 2026) · BICYCLE THERAPEUTICS PLC (BCYC)

Michael Skynner

Michael Skynner, Chief Technology Officer of Bicycle Therapeutics plc, received total compensation of $2,327,010 for fiscal year 2025. This amount included a base salary of $612,471, cash bonus/incentive of $319,355, and stock-based compensation of $1,326,470.

FY2025 is the first fiscal year CompBrief holds for Michael Skynner as a named executive officer of BICYCLE THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,327,010

Compensation figures as of the proxy filed April 22, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-09-24.

Michael Skynner compensation by year

BICYCLE THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as BICYCLE THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$612,471
Bonus$0
Stock awards$490,000
Option awards$836,470
Non-equity incentive$319,355
Pension and deferred compensation$0
All other$68,714
Total$2,327,010

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BICYCLE THERAPEUTICS PLC DEF 14A filed April 22, 2026, accession 0001104659-26-046806, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU35,000$247,800—
RSU15,750$111,510—
RSU5,469$38,721—
RSU938$6,641—
Option87,000—$14.00
Option625—$60.87
Option29,167—$18.08
Option9,480—$29.60

Per the Outstanding Equity Awards at Fiscal Year-End table in BICYCLE THERAPEUTICS PLC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2025 proxy (filed April 22, 2026)
current to 2026-09-24 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-07-15Grant or award derivative—60,000$0.0060,000
2026-07-06Sale—532$4.31157,171
2026-07-02Sale—1,859$4.27157,703

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

BICYCLE THERAPEUTICS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Kevin LeeChief Executive Officer$6,341,473
Michael Skynner · this pageChief Technology Officer (2025); Chief Scientific Officer (effective January 1, 2026)$2,327,010
Alistair MilnesChief Operating Officer (2025); Chief Corporate Development Officer (effective March 17, 2026)$2,292,424

The full BICYCLE THERAPEUTICS compensation record

free company brief

This page is one person within BICYCLE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BICYCLE THERAPEUTICS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BICYCLE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy